RT info:eu-repo/semantics/article
T1 Hospitalized COVID-19 patients with severe acute respiratory syndrome: A population-based registry analysis to assess clinical findings, pharmacological treatment and survival
A1 Gutiérrez Abejón, Eduardo
A1 Herrera Gómez, Francisco Magno
A1 Pedrosa Naudín, M. Aránzazu
A1 Tamayo Gómez, Eduardo
A1 Álvarez González, Francisco Javier
K1 SARS-CoV-2
K1 COVID-19
K1 SARS (Disease)
K1 Syndromes
K1 Clinical findings
K1 Pharmacotherapy
K1 Survival
K1 Supervivencia
K1 Virology
K1 3209 Farmacología
K1 32 Ciencias Médicas
K1 2420 Virología
AB Background and Objectives: One of the most serious clinical outcomes in hospitalized patients with COVID-19 is severe acute respiratory syndrome (SARS). The aim is to analyze pharmacological treatment, survival and the main mortality predictors. Materials and Methods: A real-world data study from COVID-19-hospitalized patients with SARS from 1 March to 31 May 2020 has been carried out. Variables such as hospital length of stay, ventilation type and clinical outcomes have been taken into account. Results: In Castile and Leon, 14.03% of the 7307 in-hospital COVID-19 patients developed SARS, with a mortality rate of 42.53%. SARS prevalence was doubled in males compared to females, and 78.54% had an age of 65 years or more. The most commonly used medicines were antibiotics (89.27%), antimalarials (68.1%) and corticosteroids (55.9%). Survival of patients developing SARS was lower compared to patients without this complication (12 vs. 13 days). The main death predictors were disseminated intravascular coagulation (DIC) (OR: 13.87) and age (>65 years) (OR: 7.35). Conclusions: Patients older than 65 years who develop DIC have a higher probability of hospital death. Tocilizumab and steroids have been linked to a lower incidence of hospital death, being the main treatment for COVID-19 hospitalized patients with SARS.
PB MDPI
SN 1648-9144
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/61877
UL https://uvadoc.uva.es/handle/10324/61877
LA eng
NO Medicina, 2022, Vol. 58, Nº. 6, 829
NO Producción Científica
DS UVaDOC
RD 26-sep-2024